Kidney Cancer

Laparoscopic Nephrectomy May Be Performed as Outpatient Surgery

Laparoscopic Nephrectomy May Be Performed as Outpatient Surgery

Most patients discharged home within first 6 hours after surgery; none readmitted.

Cabozantinib Shows Superiority in Treating Advanced mRCC

Cabozantinib Shows Superiority in Treating Advanced mRCC

By

The drug significantly improves overall and progression-free survival compared with everolimus, researchers report.

Early Tumor Shrinkage Predicts mRCC Treatment Outcomes

Early Tumor Shrinkage Predicts mRCC Treatment Outcomes

By

The optimal tumor shrinkage threshold for predicting overall and progression-free survival is 10%, researchers concluded.

Achieving 4 Lifestyle Standards May Reduce Cancer Mortality

Achieving 4 Lifestyle Standards May Reduce Cancer Mortality

Four key lifestyle factors include weight, exercise, no smoking, and limiting alcohol.

Leisure Activity Linked With Lower Risk of Several Cancers

Leisure Activity Linked With Lower Risk of Several Cancers

Findings for self-reported leisure-time physical activity of moderate to vigorous intensity.

Higher Cancer Risk in Dialysis Patients Confirmed

Higher Cancer Risk in Dialysis Patients Confirmed

By

The risk is most elevated among individuals aged 44 years or younger.

Survival Advantage Confirmed for Nephrectomy in mRCC

Survival Advantage Confirmed for Nephrectomy in mRCC

By

About 25% of patients who present with metastatic renal cancer will undergo nephrectomy after diagnosis.

Cytoreductive Nephrectomy Benefits Select mRCC Patients Taking TT

Cytoreductive Nephrectomy Benefits Select mRCC Patients Taking TT

By

Among patients treated with targeted therapy, overall survival was 17.1 months for CN recipients vs 7.7 months for those without CN.

More mRCC Patients Receiving Treatment

More mRCC Patients Receiving Treatment

By

Cytoreductive nephrectomy (CN) use remained stable in the targeted therapy era, but more patients are receiving a combination of CN and systemic therapy.

Partial Nephrectomy Feasible for T3a Renal Cell Carcinoma

Partial Nephrectomy Feasible for T3a Renal Cell Carcinoma

By

Study shows no meaningful differences between partial and radical nephrectomy in 5-year rates of local recurrence or cancer-related death.

Aspirin Safe for Partial Nephrectomy Patients

Aspirin Safe for Partial Nephrectomy Patients

Findings among patients on chronic antiplatelet therapy for cardioprotection.

Positive Margins After Partial Nephrectomy Raises Death Risk

Positive Margins After Partial Nephrectomy Raises Death Risk

By

Positive surgical margins are associated with a significant 34% increased risk of all-cause mortality.

Higher NLR Predicts More Aggressive Kidney Cancer

Higher NLR Predicts More Aggressive Kidney Cancer

By

Elevated neutrophil-to-lymphocyte ratio is associated with larger tumors and greater nuclear grade.

Partial Nephrectomy Protects Against ESRD

Partial Nephrectomy Protects Against ESRD

By

Nephron-sparing surgery decreased the risk of end-stage renal disease by 60% in select patients.

Proteinuria Signals Renal Function Decline in Kidney Cancer

Proteinuria Signals Renal Function Decline in Kidney Cancer

Proteinuria is a predictor for renal functional decline in patients with kidney cancer.

Core-Needle Biopsy Aids RCC Diagnosis

Core-Needle Biopsy Aids RCC Diagnosis

Image-guided testing of tissue from the renal mass may lead to improved treatments, researchers say.

Papillary RCC More Common in African Americans

Papillary RCC More Common in African Americans

By

Racial difference found among patients undergoing robotic partial nephrectomy for renal tumors.

Papillary RCC More Common in African Americans

Papillary RCC More Common in African Americans

By

Racial difference found among patients undergoing robotic partial nephrectomy for renal tumors.

Renal Mass Biopsy for a Small Renal Mass Can Be Accurate

Renal Mass Biopsy for a Small Renal Mass Can Be Accurate

Between renal mass biopsy, surgical pathology, rate of accuracy in identifying malignancies 97.1%.

Renal Mass Biopsy for a Small Renal Mass Can Be Accurate

Renal Mass Biopsy for a Small Renal Mass Can Be Accurate

Between renal mass biopsy, surgical pathology, rate of accuracy in identifying malignancies 97.1%.

Prostate Cancer Risk Lower in Type 2 Diabetics

Prostate Cancer Risk Lower in Type 2 Diabetics

By

In contrast, type 2 diabetes is associated with increased risks of bladder, kidney, liver, and other malignancies.

Robotic Nephrectomy of Kidney Tumors With Thrombi Feasible

Robotic Nephrectomy of Kidney Tumors With Thrombi Feasible

A retrospective study has shown that the procedure is feasible and was performed safely in selected patients with renal tumors.

Adjuvant Therapies: Time to Fold or Double Down?

Adjuvant Therapies: Time to Fold or Double Down?

Benjamin T Ristau, MD, and Robert G. Uzzo, MD, FACS, examine why adjuvant therapies have been so ineffective.

Researchers Calculate Inherited Cancer Risk from Genes

Researchers Calculate Inherited Cancer Risk from Genes

Estimated 33% of overall risk is genetic; certain types of cancer have additional risk.

NSAIDs May Raise Risk of Fatal Kidney Cancer

NSAIDs May Raise Risk of Fatal Kidney Cancer

By

Regular use of non-steroidal anti-inflammatory drugs for 10 years or more increased the risk of dying from renal cell carcinoma nearly 4-fold.

NSAIDs May Raise Risk of Fatal Kidney Cancer

NSAIDs May Raise Risk of Fatal Kidney Cancer

By

Regular use of non-steroidal anti-inflammatory drugs for 10 years or more increased the risk of dying from renal cell carcinoma nearly 4-fold.

Nephrectomy as Initial mRCC Treatment Offers Survival Advantage

Nephrectomy as Initial mRCC Treatment Offers Survival Advantage

By

Patients who underwent upfront cytoreductive nephrectomy lived 6.4 months longer than those treated with upfront targeted therapy, a study found.

Nephrectomy as Initial mRCC Treatment Offers Survival Advantage

Nephrectomy as Initial mRCC Treatment Offers Survival Advantage

By

Patients who underwent upfront cytoreductive nephrectomy lived 6.4 months longer than those treated with upfront targeted therapy, a study found.

Metformin Lowers Death Risk in mRCC Patients on Sunitinib

Metformin Lowers Death Risk in mRCC Patients on Sunitinib

By

The protective effect was not observed with other anti-diabetic medications.

Metformin Lowers Death Risk in mRCC Patients on Sunitinib

Metformin Lowers Death Risk in mRCC Patients on Sunitinib

By

The protective effect was not observed with other anti-diabetic medications.

Sign Up for Free e-newsletters